AHA comments on ensuring legitimate access to controlled substances
The AHA today responded to a Department of Health and Human Services request for input from health care providers and other stakeholders on ensuring legitimate access to controlled substances, including opioids, while preventing diversion and abuse. The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 calls for HHS’ Office of the Assistant Secretary for Planning and Evaluation to submit a report to Congress on the issue. Among other actions, AHA recommends providing additional support for medical education, training and guidance for non-opioid pain management as well as for state drug courts, which offer justice-involved individuals with substance use disorders the opportunity to enter treatment programs.
Related News Articles
Headline
The Federal Trade Commission announced Sept. 9 that it rescinded its 2021 policy statement that extended applicability of its health breach notification rule…
Headline
The Department of Health and Human Services Sept. 4 announced that it awarded $11.2 million in grants to 15 recipients across 14 states to develop new…
Headline
The AHA Aug. 28 shared concerns with the Centers for Medicare & Medicaid Services regarding the calendar year 2027 hospital outpatient prospective payment…
Headline
The AHA provided comments to the Centers for Medicare & Medicaid Services Aug. 28 on its calendar year 2027 home health prospective payment system proposed…
Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
The Department of Homeland Security today released a proposed rule to establish a new $103,265 filing fee for H-1B visa petitions that are subject to statutory…